Last updated: June 2, 2026
Executive summary: Public supplier visibility for ciprofloxacin + dexamethasone is uneven because the combination is marketed in different dosage forms (most commonly ophthalmic suspensions/ointments) and at different labeled strengths across markets. At the finished-dose level, supplier lists depend on the specific NDA/ANDA, strength, and country. At the IP and manufacturing level, the supply chain is split between (1) active pharmaceutical ingredient (API) manufacturers for ciprofloxacin and dexamethasone, and (2) contract manufacturers/formulators that produce the finalized sterile ophthalmic product (typically via aseptic processing and fill-finish).
Result: A complete, actionable “supplier list” requires tying “supplier” to a specific product and market (ANDA/NDA holder, finished-dose site, API/sterile fill-finish contract sites). The only way to produce a complete and accurate answer is to name the exact marketed product(s) and their FDA/Orange Book identities and/or international equivalents. With only the generic description “ciprofloxacin and dexamethasone,” a complete supplier roster cannot be produced without risking omissions or misattribution.
What suppliers provide ciprofloxacin and dexamethasone APIs for the ophthalmic combination?
Featured snippet answer: Ciprofloxacin and dexamethasone are typically supplied by multiple global API manufacturers, while the finished ophthalmic combination is supplied by branded and generic product holders who contract sterile manufacturing and fill-finish.
Which API grades are used for ophthalmic ciprofloxacin + dexamethasone products?
- Ciprofloxacin API: usually provided as a pharmaceutical-grade crystalline API with defined polymorph control, particle size specs, and impurity limits appropriate for ocular use.
- Dexamethasone API: typically supplied as a steroid API with tight impurity and water content controls.
How does API supply differ from finished-dose supply?
- API supply is global and mostly driven by compliance with GMP, DMF filings, and pharmacopeial specs.
- Finished-dose supply is tied to sterile manufacturing capacity, validated aseptic processes, packaging, and stability for suspensions or solutions.
Which finished-dose companies supply ciprofloxacin + dexamethasone ophthalmic drugs (US and major markets)?
Featured snippet answer: Finished-dose supply is concentrated among NDA holders and generic ANDA filers for specific strengths and dosage forms, with each product linked to one or more labeled manufacturers and fill-finish sites.
What dosage forms exist for the combination?
Common labeled forms include:
- Ophthalmic suspension
- Ophthalmic ointment
Why do suppliers vary by strength and country?
The same active combination can be sold as different:
- strengths (mg/mL)
- suspension vs ointment
- preservative system
- packaging type (bottle vs unit-dose)
Different formulations usually map to different manufacturing sites and ANDA/NDA holders.
How do you identify the true manufacturers and fill-finish sites for ciprofloxacin + dexamethasone generics?
Featured snippet answer: Use the FDA Orange Book and the FDA labeling/CMC references for the specific product strength and dosage form, then cross-check the listed manufacturer(s) and any linked manufacturing site addresses in the FDA data system.
Data sources typically used by compliance and procurement teams
- FDA Orange Book: identifies the approved drug product and lists applicant/holder.
- FDA prescribing information and labeling: identifies manufacturer name and address on cartons/leaflets.
- FDA application databases (NDA/ANDA records): link to manufacturing and, sometimes, DMF references.
- DMF references (for API): map to API applicants and manufacturing information.
What about biosimilar or biologic risk for ciprofloxacin + dexamethasone?
Featured snippet answer: There is no biosimilar concept for ciprofloxacin or dexamethasone because both are small molecules. Supply risk is instead driven by chemical API manufacturing capacity, DMF status, quality investigations, and sterile fill-finish constraints.
What patents protect the ciprofloxacin + dexamethasone combination, and do they affect supplier eligibility?
Featured snippet answer: Patent protection, if any, typically affects marketing approval timing and ANDA entry. It does not usually block API supply, but it can limit finished-dose market entry and licensing.
Where patent status matters for suppliers
- Patent thickets can affect which generic applicants can launch.
- Settlement agreements can shift launch sequencing among competing ANDAs.
- Formulation and method-of-manufacture patents can constrain process changes and packaging.
When do generics of ciprofloxacin + dexamethasone typically lose exclusivity and launch?
Featured snippet answer: Generic timing is determined per product by:
- Orange Book-listed patents and expiration dates
- exclusivity periods tied to the original approval (if applicable)
- any Paragraph IV litigation/settlement
Without naming the exact marketed product(s) and strength/dosage form, a credible exclusivity or launch timeline cannot be produced.
What generic entry risks exist for ciprofloxacin + dexamethasone ophthalmic suspensions?
Featured snippet answer: The primary risks are regulatory and CMC:
- sterility assurance for suspensions
- particle size distribution and re-suspendability
- preservative compatibility
- stability and shelf life across packaging
How does supply chain structure affect pricing for ciprofloxacin + dexamethasone?
Featured snippet answer: Pricing pressure is driven by:
- API market structure (multiple capable sources)
- sterile fill-finish capacity constraints
- packaging material availability (closures, dropper units, unit-dose systems)
Key takeaways
- “Suppliers” for ciprofloxacin + dexamethasone must be specified as either API suppliers or finished-dose/manufacturing sites, and tied to a specific product strength and dosage form.
- Ciprofloxacin and dexamethasone are small molecules, so biosimilar risk does not apply; supply risk is mainly CMC/sterile manufacturing and regulatory approvals.
- A complete supplier roster cannot be produced from the generic combination name alone without mapping to exact marketed products (NDA/ANDA) and their labeled manufacturer(s) and DMF-linked API sources.
FAQs
- Which FDA-approved product identifiers (NDA/ANDA) correspond to “ciprofloxacin + dexamethasone ophthalmic suspension” at specific strengths?
- How do DMFs for ciprofloxacin and dexamethasone map to API manufacturing sites for ophthalmic products?
- What sterile fill-finish requirements drive CMC development for ophthalmic suspensions containing dexamethasone?
- Do formulation patents for ophthalmic suspensions typically cover particle size or re-suspension characteristics?
- What settlement agreements or Paragraph IV litigation most often shape generic launch timing for this combination?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
